Stockreport

Rapport Therapeutics Seeks IPO For CNS Treatment Programs [Seeking Alpha]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF The company's lead candidate, RAP-219, is being developed to treat Focal Epilepsy, peripheral nerve pain, and bipolar disorder. Rapport Therapeutics is backed by top- [Read more]